Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

ACAlpha Cognition Inc.

$8.15

+0.25 (+3.16%)

Market Cap
131.30 M
EPS
-1.18
P/E Ratio
-5.12 $
Value Trade
33.46 K
SEC Financials
Q1 2026

  • Dilution Risk

    40%

  • Revenue

    3.53 M

  • R&D Expenses

    1.10 M

  • Operating CF

    -11.80 M

  • Total Assets

    69.25 M

  • Total Liabilities

    11.79 M

  • Equity

    57.46 M

  • D/E Ratio

    12,345

-12.6 %
Week
-12.76 %
1 Month
-49.58 %
3 Month
-64.3 %
6 Month
-98.92 %
5 Year
-98.92 %
All Time
Cash Data
Caution

  • Cash Position

    54.25 M

  • Monthly Burn

    3.93 M

  • Runway

    11.6 mo

  • Burn Trend

    Accelerating

  • SEC Filing

    May 14, 2026
Overview
Volume
147.33 K
52 Week Range
3.97 - 11.54
% held by Insiders
8.48 %
% held by Institutions
77.22 %
Enterprise Value
65.19 M
Total Shares
21.73 M
Short %
0.91 %
Float Shares
19.08 M
Company Description
HQ: 1452 HUGHES RD., STE. 200, GRA...
Employees:71
https://www.alphacognition.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
PDUFA 2026
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%

FDA review of the new drug application for the treatment of example condition.

Read More
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%

FDA review of the new drug application for the treatment of example condition.

Read More
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%

FDA review of the new drug application for the treatment of example condition.

Read More
Small Molecule
Oncology
Unlock Upcoming Catalyst data

Catalyst Timeline

Dated clinical, regulatory & corporate events for Alpha Cognition Inc.

40Total events
1Upcoming
8Tier-1 (high impact)
2021 – 2026Coverage

Upcoming catalysts 1

TBD
T1Topline Readout
Subscribe to view catalyst details
ZUNVEYLApproved

Event history 2

TBD
◆Oral PresentationPresentation
Subscribe to view catalyst details
TBD
◆Management ChangeCorporate
Subscribe to view catalyst details
Unlock the full Catalyst Timeline
Past FDA Catalysts & PDUFA Decisions
Date Drug Catalyst Stage Outcome Reaction Event Move % Best Trade %
2024-07-26
Zunveyl (benzgalantamine gluconate)
PDUFA Date
PDUFA
Approved
–
–
–
2024-07-26
Zunveyl (benzgalantamine gluconate)
PDUFA Date
PDUFA
Approved
–
–
–
2024-07-26
Zunveyl (benzgalantamine gluconate)
PDUFA Date
PDUFA
Approved
–
–
–
Unlock Historical Catalyst data
Drug Pipeline Intelligence
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01

The study met its primary endpoint demonstrating statistically significant improvement.

Read More

Phase 3 Study Results Announcement

Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01

The study met its primary endpoint demonstrating statistically significant improvement.

Read More

Phase 3 Study Results Announcement

Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01

The study met its primary endpoint demonstrating statistically significant improvement.

Read More

Phase 3 Study Results Announcement

Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in ACOG
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
ACOG Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-09-180 0.00 0 0 - - - - - -
2026-09-180 0.00 0 0 - - - - - -
2026-09-180 0.00 0 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-ACOG
Jul 10, 2026
ACOGConferences/Events

Alpha Cognition to Participate in Panel Discussion at the B. Riley Securities Mind, Muscle & Vision Summit

Alpha Cognition Inc. will have its CEO, Michael McFadden, participate in a panel discussion at the B. Riley Securities Mind, Muscle & Vision Summit. This event is scheduled for July 16th in Boston, Massachusetts, and focuses on late-stage and commercial CNS therapies. The participation highlights Alpha Cognition's commitment to addressing neurodegenerative disorders.

Read more →
-ACOG
Jun 23, 2026
ACOGGeneral

Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board

Alpha Cognition has announced the election of Dr. Robert Wills as the new Chairman of the Board. This leadership change is expected to influence the company's strategic direction. Further details regarding Dr. Wills' vision for the company were not disclosed in the announcement.

Read more →
-ACOG
Jun 16, 2026
ACOGPhases

Alpha Cognition Announces First Patient Enrolled in RESOLVE Phase 4 Study Evaluating ZUNVEYL® in Patients with Mild to Moderate Alzheimer’s Disease

Alpha Cognition has announced the enrollment of the first patient in its RESOLVE Phase 4 study. This study aims to evaluate the efficacy of ZUNVEYL® in patients diagnosed with mild to moderate Alzheimer's disease. The trial represents a significant step in exploring new treatment options for this patient population.

Read more →
-ACOG
Jun 9, 2026
ACOGGeneral

Alpha Cognition Reports Positive Top-Line Results from BEACON Real-World Study of ZUNVEYL® in Alzheimer’s Disease

Alpha Cognition has announced positive top-line results from the BEACON real-world study of ZUNVEYL® in Alzheimer's Disease. The findings suggest that ZUNVEYL® may be effective in addressing symptoms associated with this condition. This development marks a significant step forward for the company in its efforts to provide solutions for Alzheimer's patients.

Read more →
-ACOG
May 14, 2026
ACOGGeneral

Alpha Cognition Inc. Reports First Quarter 2026 Financial Results and Provides Operational Update

Alpha Cognition Inc. has released its financial results for the first quarter of 2026 and provided an operational update. However, the article lacks specific details regarding the financial performance or operational changes. The information presented does not indicate any significant positive or negative developments.

Read more →
-ACOG
Apr 28, 2026
ACOGConferences/Events

Alpha Cognition (Nasdaq: ACOG) to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, May 14, 2026

Alpha Cognition Inc. will report its first quarter 2026 financial results and provide a business update on May 14, 2026. A press release detailing these results will be available on their website, followed by a conference call for management to discuss the outcomes. The company focuses on treatments for neurodegenerative diseases, including Alzheimer's.

Read more →
-ACOG
Apr 27, 2026
ACOGConferences/Events
▼ -6.2%on this newsshared move

Alpha Cognition Inc. to Participate in Three Upcoming Investor Conferences

Alpha Cognition Inc. announced its participation in three upcoming investor conferences in May, with CEO Michael McFadden presenting. The events include the Market Movers Investor Summit, H.C. Wainwright BioConnect Conference, and Craig Hallum's Institutional Investor Conference. The company is focused on developing treatments for neurodegenerative diseases, including its drug ZUNVEYL for Alzheimer's.

Read more →
-ACOG
Apr 21, 2026
ACOGGeneral

Alpha Cognition Strengthens Its Board of Directors with Appointment of Bethany Sensenig

Alpha Cognition Inc. has appointed Bethany Sensenig to its Board of Directors, effective April 15, 2026. Sensenig brings extensive experience from her previous roles in the pharmaceutical industry, which will support the company's efforts in launching ZUNVEYL and developing its sublingual program. The company also announced that Len Mertz will not seek re-election to the board.

Read more →
-ACOG
Apr 16, 2026
ACOGGeneral

Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 15, 2026

Alpha Cognition Inc. announced the grant of stock options to a new employee under its 2026 Inducement Grant Plan. The Compensation Committee approved the grant as part of the company's strategy to attract talent while adhering to Nasdaq Listing Rule 5635(c)(4). Each stock option will vest over three years, aligning with the company's commitment to developing treatments for neurodegenerative diseases.

Read more →
-ACOG
Apr 16, 2026
ACOGGeneral

Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Alpha Cognition has reported inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4). The details surrounding these grants were not elaborated upon in the article. The announcement is part of the company's compliance with regulatory requirements.

Read more →
-ACOG
Apr 1, 2026
ACOGFDA Updates
▲ +8.6%on this news· ran to +27% by day 3

Alpha Cognition Receives Issued U.S. Patent for ALPHA-1062 for Treatment of Traumatic Brain Injury

Alpha Cognition Inc. has received a U.S. patent for ALPHA-1062, aimed at treating traumatic brain injury (TBI). This patent, effective until 2045, bolsters the company's intellectual property and supports its strategy to expand beyond Alzheimer's disease. The TBI market presents a significant opportunity, with no approved therapies currently available.

Read more →
-ACOG
Mar 26, 2026
ACOGGeneral

Alpha Cognition Inc. Reports Fiscal 2025 Financial Results and Provides Operational Update

Alpha Cognition Inc. has reported its financial results for fiscal year 2025 and provided an operational update. The article lacks specific details regarding the financial performance or operational changes. Overall, the content does not present any significant positive or negative insights.

Read more →
-ACOG
Mar 26, 2026
ACOGGeneral

Alpha Cognition Inc. Nasdaq: ACOG 1452 Hughes Road, Ste. 200 Grapevine, TX 65051 www.alphacognition.com info@alphacognition.com Alpha Cognition Inc. Reports Fiscal 2025 Financial Results and Provides Operational Update A

Alpha Cognition Inc. reported its fourth quarter and full year financial results for 2025, highlighting strong commercial performance with ZUNVEYL, which saw a significant increase in revenue and product dispensation. The company established two national PBM contracts and is focused on further expanding its market presence in Alzheimer's treatment. Despite a positive outlook with increasing adoption and financial reserves, the company acknowledged safety concerns related to serious skin reactions and potential cardiac effects. A conference call was held to discuss these results and future prospects.

Read more →
-ACOG
Feb 26, 2026
ACOGPhases
▼ -5.3%on this news

Alpha Cognition Announces First Patient Enrolled in BEACON Real-World Effectiveness Study

Alpha Cognition Inc. has announced the enrollment of the first patient in the BEACON study, which aims to evaluate the real-world effectiveness of ZUNVEYL in patients with Alzheimer's disease in long-term care settings. This Phase 4 study will gather data on cognition, neuropsychiatric symptoms, and safety, contributing to the ongoing evaluation of ZUNVEYL. The company anticipates reporting topline results in late 2026.

Read more →
-ACOG
Feb 18, 2026
ACOGFDA Updates
▲ +11.3%on this news

Alpha Cognition Announces Issuance of Additional U.S. Patent Covering ZUNVEYL ® Dosing Regimens

Alpha Cognition Inc. has announced the issuance of a new U.S. patent covering dosing regimens for benzgalantamine, aimed at treating mild to moderate Alzheimer's disease. This patent, which extends protection until July 2045, enhances the company's intellectual property portfolio and supports the commercial value of its FDA-approved therapy, ZUNVEYL. The CEO emphasized the significance of this patent in differentiating ZUNVEYL in the market.

Read more →
-ACOG
Dec 2, 2025
ACOGConferences/Events

Alpha Cognition to Participate in Virtual Fireside Chat Hosted by Titan Partners

Alpha Cognition Inc. will participate in a virtual fireside chat hosted by Titan Partners, focusing on its commercialization efforts and research initiatives. The event is scheduled for December 2, 2025, featuring CEO Michael McFadden. The company is dedicated to developing treatments for neurodegenerative diseases, including its FDA-approved drug ZUNVEYL for Alzheimer's disease.

Read more →
-ACOG
Sep 30, 2025
ACOGGeneral

Alpha Cognition Inc. Announces Proposed Public Offering of Common Shares VANCOUVER, BC and Dallas, TX

Alpha Cognition Inc. announced a proposed public offering of its common shares aimed at accelerating its commercial launch and expanding its marketing efforts for its Alzheimer's treatment, ZUNVEYL. The offering includes a 30-day option for the underwriter to purchase additional shares. As the offering is contingent on market conditions, uncertainties regarding its completion and terms remain. The funds raised are intended for enhancing reimbursement infrastructure and maximizing near-term adoption in the market.

Read more →
-ACOG
May 15, 2025
ACOGGeneral

Alpha Blue Erection Formula Under Review: Blue Salt Trick Recipe for Nitric Boost

The article discusses the Alpha Blue Erection Formula, which is currently under review and emphasizes the trending Blue Salt Trick. This non-prescription remedy aims to enhance nitric oxide levels, potentially improving male performance and vitality. While it outlines the benefits of the formulation and user testimonials, the article notes that individual results may vary. Additionally, it encourages readers to inform themselves about the product through transparent insights and available options.

Read more →
-ACOG
May 9, 2025
ACOGGeneral

Alpha Surge Under Review: What the Ingredients, Benefits & Side Effects Risk Say About AlphaSurge

Alpha Surge is a natural male vitality supplement that aims to support testosterone function, enhance energy, and improve libido. Comprised of a blend of ingredients like L-Arginine and Tongkat Ali, it is designed to address common vitality issues faced by men, particularly those over 30. The supplement is marketed as a cleaner alternative to traditional testosterone boosters, free from stimulants and synthetic hormones. While individual results can differ, Alpha Surge comes with a 90-day money-back guarantee and positive customer feedback regarding its effectiveness.

Read more →
-ACOG
May 6, 2025
ACOGGeneral

Alpha Drive RX Under Review: The Alpha Drive Performance Enhancement Gummies for Men

Alpha Drive RX, a male enhancement supplement, is designed to improve stamina and sexual performance using natural ingredients like L-Arginine and Asian Red Ginseng. It promises benefits such as stronger erections and increased libido, with many users reporting positive experiences. The supplement is made in a certified facility and offers a money-back guarantee, making it an appealing option for men facing sexual performance issues.

Read more →
-ACOG
Apr 22, 2025
ACOGGeneral
▲ +8.3%on this news· ran to +20% by day 3

AlphaCur Under Review: Advanced Nutritional Support for Neuropathy Nerve Health

AlphaCur is introduced as an innovative nutritional supplement aimed at providing support for individuals suffering from neuropathy. It addresses the underlying causes of nerve damage, such as inflammation and oxidative stress, rather than just masking symptoms. The product aims to promote long-term nerve health and regeneration through its science-backed formulation. Additionally, AlphaCur is manufactured in a GMP-certified facility in the USA, emphasizing safety and quality.

Read more →
-ACOG
Apr 17, 2025
ACOGGeneral

Alpha Tonic Under Review: Himalayan Tonic T-Booster Powder to Increase Testosterone Naturally

Alpha Tonic, a new powdered supplement inspired by Himalayan traditions, aims to naturally increase testosterone levels in men. As testosterone decline becomes increasingly common among younger generations, this product presents a plant-based alternative to synthetic hormone therapies. The tonic is formulated to improve energy, stamina, muscle strength, and sexual performance while avoiding synthetic ingredients. Users are encouraged to integrate Alpha Tonic into their daily routine for optimal results.

Read more →
-ACOG
Apr 12, 2025
ACOGGeneral
▲ +10.4%on this newsshared move

Alpha Bites Ingredients Under Review: Best Male Enhancement Gummies Brand on the Market

The article discusses the rising market for male enhancement supplements, highlighting Alpha Bites Male Enhancement Gummies as a promising, natural solution. These gummies are designed to address common issues faced by men, such as low stamina and diminished libido, through a formulation based on scientific research. The product emphasizes ingredient transparency, safety in manufacturing, and customer satisfaction with a money-back guarantee. Their innovative delivery system aims to improve compliance and performance compared to traditional supplements.

Read more →
-ACOG
Mar 17, 2025
ACOGGeneral

Alpha Bites Gummies: The Science, Ingredients, and Real User Experiences Behind This Natural Male Vitality Formula

Alpha Bites Gummies is a natural supplement designed to enhance male vitality by addressing root causes such as low energy and hormonal imbalances. With ingredients like Tongkat Ali, Horny Goat Weed, and Maca Root, the product targets stamina, energy levels, and sexual health. Available online, the gummies offer a convenient daily solution with a risk-free trial period. The formulation is positioned as a holistic alternative to conventional male health supplements that rely on synthetic stimulants.

Read more →
-ACOG
Feb 5, 2025
ACOGGeneral

Alpha Bites: Reviews, Ingredients, Studies and Where to Buy

Alpha Bites, a new supplement aimed at enhancing men's vitality, combines natural ingredients like Catuaba Extract, Beet Root Powder, and Horny Goat Weed Extract to tackle common performance challenges. It focuses on long-term benefits rather than temporary energy boosts, appealing to men across various age groups. The product has gained traction on social media and health forums as a promising solution for issues related to stamina and confidence, reinforced by a satisfaction guarantee. With research backing its ingredients, Alpha Bites aims to shift the paradigm in men's health from quick fixes to sustainable, science-based wellness strategies.

Read more →
-ACOG
Aug 21, 2024
ACOGGeneral

ALPHA COGNITION INC. c/o 1200 - 750 West Pender Street Vancouver, BC V6C 2T8 MANAGEMENT INFORMATION CIRCULAR as at

Alpha Cognition Inc. released a management information circular detailing the solicitation of proxies for its upcoming annual general meeting scheduled for September 27, 2024. The circular includes information for registered and non-registered shareholders regarding voting procedures and proxy appointments. It highlights the company's process for handling proxies and the importance of submitting them on time, emphasizing that only registered shareholders can revoke their proxies. Non-registered shareholders are advised on how their votes will be handled through intermediaries.

Read more →
-ACOG
Aug 12, 2024
ACOGGeneral

Alpha Cognition Inc. CSE: ACOG 1200-750 W Pender St, Vancouver, BC V6C 2T8, www.alphacognition.com info@alphacognition.com NEWS RELEASE Alpha Cognition Announces Financial Results for the Second Quarter and Six Months En

Alpha Cognition Inc. has announced its financial results for the second quarter and first half of 2024, highlighting the FDA approval of its Alzheimer's treatment, ZUNVEYL. This approval is seen as a key milestone for the company, enhancing its commitment to developing innovative therapies. Despite a reported net loss, Alpha Cognition plans to focus on launching ZUNVEYL commercially while navigating potential market and regulatory challenges.

Read more →
-ACOG
Jul 29, 2024
ACOGFDA Updates

Alpha Cognition Inc. CSE: ACOG | OTCQB: ACOGF 301-1228 Hamilton Street Vancouver, BC, V6B 6L2 www.alphacognition.com info@alphacognition.com Alpha Cognition's Oral Therapy ZUNVEYL Receives FDA Approval to Treat Alzheimer

Alpha Cognition Inc. has announced that its oral therapy, ZUNVEYL, has received FDA approval for treating mild to moderate Alzheimer's disease. ZUNVEYL features a dual mechanism of action designed to eliminate drug absorption in the gastrointestinal tract, potentially addressing common tolerability issues associated with current Alzheimer's medications. With Alzheimer's affecting nearly 7 million people in the U.S., this new treatment aims to enhance cognitive function and daily living activities. ZUNVEYL is expected to be available by prescription in Q1 2025.

Read more →
-ACOG
Mar 1, 2024
ACOGConferences/Events

Alpha Cognition to Present at the Life Science Investor Forum March 7th

Alpha Cognition, a biopharmaceutical company focused on neurodegenerative disorders, announced that CEO Michael McFadden and COO Lauren D'Angelo will present at the Life Science Investor Forum on March 7, 2024. They will discuss the company's lead asset, ALPHA-1062, aimed at treating mild-to-moderate Alzheimer's disease. ALPHA-1062's NDA was filed and accepted by the FDA in December 2023, with a PDUFA date set for July 27, 2024. The event will allow for real-time interactions with investors and will also be available in an archived format post-event.

Read more →
-ACOG
Nov 28, 2022
ACOGGeneral

Alpha Cognition Announces Withdrawal of Marketed Public Offering

NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES VANCOUVER, British Columbia, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Alpha Cognition Inc. (“Alpha” or the “Company”) (TSXV:ACOG) (OTCQB: ACOGF), a biopharmaceutical company committed to developing novel thera

Read more →
-ACOG
Nov 17, 2022
ACOGGeneral

Alpha Cognition Announces Marketed Offering

NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES VANCOUVER, British Columbia, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Alpha Cognition Inc. (“Alpha” or the “Company”) (TSXV:ACOG) (OTCQB: ACOGF), a biopharmaceutical company committed to developing novel ther

Read more →
-ACOG
Jun 21, 2022
ACOGConferences/Events

Alpha Cognition to Webcast Live at VirtualInvestorConferences.com June 23rd

VANCOUVER, British Columbia, June 21, 2022 (GLOBE NEWSWIRE) -- Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders,

Read more →
-ACOG
Sep 23, 2021
ACOGGeneral

Alpha Cognition Announces Pricing of Public Offering

NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES VANCOUVER, British Columbia, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Alpha Cognition Inc. (“Alpha” or the “Company”) (TSXV:ACOG), a biopharmaceutical company committed to developing novel therapies with the

Read more →
-ACOG
Sep 22, 2021
ACOGGeneral

Alpha Cognition Announces Overnight Marketed Offering

NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES VANCOUVER, British Columbia, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Alpha Cognition Inc. (“Alpha” or the “Company”) (TSXV:ACOG), a biopharmaceutical company committed to developing novel therapies with the

Read more →
-ACOG
Sep 9, 2021
ACOGConferences/Events

Alpha Cognition to Webcast Live at Life Sciences Investor Forum September 16th

VANCOUVER, British Columbia, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Alpha Cognition, Inc. (TSX-V: ACOG)(OTCQB: ACOGF)(“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with deb

Read more →
-ACOG
Oct 16, 2012
ACOGGeneral

Alpha 7 Program to be Showcased at Neuroscience 2012

Targets Alzheimer's disease and confirms Bionomics' focus on well differentiated drug candidates targeting large markets Competitive advantages combine potency and selectivity with rapid action Compounds outperform leading drug Donepezil ADELAIDE, Australia, Oct. 16, 2012 (GLO

Read more →
Competitive Position
How ACOG ranks across every disease it competes in
Competitive Position is a premium feature
See how ACOG ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial